Zomedica director buys 200,000 shares of stock

Director Johnny D. Powers of Zomedica Corp. reported purchasing a total of 200,000 shares of common stock at $0.1030 per share in three non-derivative transactions described as purchases in open market or private transactions.

Accepted by SEC EDGAR 05/21/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Director Johnny D. Powers of Zomedica Corp. reported purchasing a total of 200,000 shares of common stock at $0.1030 per share in three non-derivative transactions described as purchases in open market or private transactions.

After these purchases, he directly holds 4,425,000 shares of Zomedica common stock. The filing indicates these trades were not made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 200,000 shares

Net Buy 3 txns

Insider POWERS JOHNNY D

Role Director

Bought 200,000 shs ($21K)

Increase in Position 4.7%

Type	Security	Shares	Price	Value
Purchase	Common Stock, without par value	100,000	$0.103	$10K
Purchase	Common stock, without par value	2,485	$0.103	$255.95
Purchase	Common Stock, without par value	97,515	$0.103	$10K

Holdings After Transaction: Common Stock, without par value — 4,425,000 shares (Direct)

Holdings Before and After: Common Stock, without par value, 4,225,000 to 4,425,000 shares (Direct)

Other Insiders: 2 other insiders reported open-market purchases of this stock in the 30 days up to this filing.

Key Figures

Aggregate shares purchased: 200,000 shares Purchase price per share: $0.1030 First transaction shares: 100,000 shares +3 more

6 metrics

Aggregate shares purchased 200,000 shares Total common shares purchased across three reported transactions

Purchase price per share $0.1030 Price per share for each reported common stock purchase

First transaction shares 100,000 shares Common Stock, without par value, non-derivative purchase

Second transaction shares 2,485 shares Common stock, without par value, non-derivative purchase

Third transaction shares 97,515 shares Common Stock, without par value, non-derivative purchase

Post-transaction holdings 4,425,000 shares Direct common stock holdings after the reported purchases

Key Terms

non-derivative, open market or private transaction, Rule 10b5-1

3 terms

non-derivative financial

"transaction_type is noted as "non-derivative" for the common stock purchases"

open market or private transaction financial

"described as a "Purchase in open market or private transaction""

Rule 10b5-1 regulatory

"document-level Rule 10b5-1 checkbox (aff_10b5_one) was not selected"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ZOMDF director Johnny D. Powers report?

Johnny D. Powers, a director of Zomedica Corp. (ZOMDF), reported purchasing a total of 200,000 common shares at $0.1030 per share across three non-derivative transactions classified as purchases in open market or private transactions.

How many ZOMDF shares does Johnny D. Powers hold after these transactions?

After the reported purchases, Johnny D. Powers directly holds 4,425,000 shares of Zomedica common stock. This figure reflects his post-transaction position in common stock, as shown in the canonical holdings linked to the insider filing.

Were the ZOMDF insider purchases made under a Rule 10b5-1 plan?

The filing indicates the Rule 10b5-1 checkbox was not selected, meaning these Zomedica (ZOMDF) share purchases were not affirmed as being made pursuant to a pre-established Rule 10b5-1 trading plan, based on the document-level certification field.

At what price were the ZOMDF shares purchased in this Form 4?

Each of the three reported transactions for Zomedica (ZOMDF) common stock lists a purchase price of $0.1030 per share. The transactions are identified as non-derivative open market or private purchases at this same per-share price level.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POWERS JOHNNY D

(Last) (First) (Middle)

1101 TECHNOLOGY DRIVE

STE 100

(Street)

ANN ARBOR. MICHIGAN 48108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, without par value	05/18/2026		P		100,000	A	$0.103	4,325,000	D
Common stock, without par value	05/19/2026		P		2,485	A	$0.103	4,327,485	D
Common Stock, without par value	05/20/2026		P		97,515	A	$0.103	4,425,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/Johnny D. Powers	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)